Anish A Patel1, Arvind J Trindade2, David L Diehl3, Harshit S Khara3, Tai-Ping Lee2, Calvin Lee2, Amrita Sethi1. 1. Columbia University Medical Center, Division of Digestive and Liver Disease, New York, NY, USA. 2. Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, Division of Gastroenterology, Long Island Jewish Medical Center, New Hyde Park, NY, USA. 3. Department of Gastroenterology, Geisinger Medical Center, Danville, PA, USA.
Abstract
BACKGROUND: Argon plasma coagulation (APC) is typically the first-line therapy for gastric antral vascular ectasia (GAVE). However, many patients are refractory to APC ablation. OBJECTIVE: We examined the safety and efficacy of nitrous oxide CryoBalloon cryotherapy ablation for GAVE refractory to APC. METHODS: This is a retrospective review of patients with refractory GAVE treated with the CryoBalloon system. Technical success was defined as successful ablation of the visualized GAVE. Clinical success was defined by transfusion independence and percentage of GAVE that was eradicated. RESULTS: Twenty-three patients with GAVE were included, of whom 16 patients (70%) had two treatments with the CryoBalloon and seven patients (30%) had one treatment. Technical success was achieved in all patients. At six months, 19/23 (83%) were transfusion independent, while 20/23 (87%) had more than 75% of the GAVE eradicated. Patients were transfused an average of 1.8 units/month one year prior to cryotherapy and an average of 0.3 units/month up to six months post-cryotherapy (p < 0.001). The average increase in mean hemoglobin at six months was 2.55 g/dl. No acute or late adverse events were reported. CONCLUSIONS: CryoBalloon ablation is an efficacious and safe modality for the treatment of GAVE. Prospective studies need to be conducted to determine comparative results to standard therapies.
BACKGROUND: Argon plasma coagulation (APC) is typically the first-line therapy for gastric antral vascular ectasia (GAVE). However, many patients are refractory to APC ablation. OBJECTIVE: We examined the safety and efficacy of nitrous oxide CryoBalloon cryotherapy ablation for GAVE refractory to APC. METHODS: This is a retrospective review of patients with refractory GAVE treated with the CryoBalloon system. Technical success was defined as successful ablation of the visualized GAVE. Clinical success was defined by transfusion independence and percentage of GAVE that was eradicated. RESULTS: Twenty-three patients with GAVE were included, of whom 16 patients (70%) had two treatments with the CryoBalloon and seven patients (30%) had one treatment. Technical success was achieved in all patients. At six months, 19/23 (83%) were transfusion independent, while 20/23 (87%) had more than 75% of the GAVE eradicated. Patients were transfused an average of 1.8 units/month one year prior to cryotherapy and an average of 0.3 units/month up to six months post-cryotherapy (p < 0.001). The average increase in mean hemoglobin at six months was 2.55 g/dl. No acute or late adverse events were reported. CONCLUSIONS: CryoBalloon ablation is an efficacious and safe modality for the treatment of GAVE. Prospective studies need to be conducted to determine comparative results to standard therapies.
Authors: Dirk W Schölvinck; Hannah T Künzli; Christine Kestens; Peter D Siersema; Frank P Vleggaar; Marcia Irene Canto; Hilary Cosby; Julian A Abrams; Charles J Lightdale; Elizabeth Tejeda-Ramirez; Steven R DeMeester; Christine L Greene; Blair A Jobe; Jeff Peters; Jacques J G H M Bergman; Bas L A M Weusten Journal: Endoscopy Date: 2015-07-09 Impact factor: 10.093
Authors: Sergey V Kantsevoy; Marcia R Cruz-Correa; Cheryl A Vaughn; Sanjay B Jagannath; Pankaj J Pasricha; Anthony N Kalloo Journal: Gastrointest Endosc Date: 2003-03 Impact factor: 9.427
Authors: Sarah Cho; Simon Zanati; Elaine Yong; Maria Cirocco; Gabor Kandel; Paul Kortan; Gary May; Norman Marcon Journal: Gastrointest Endosc Date: 2008-07-21 Impact factor: 9.427
Authors: Amaninder Dhaliwal; Syed M Saghir; Harmeet S Mashiana; Annie Braseth; Banreet S Dhindsa; Daryl Ramai; Pushpak Taunk; Rene Gomez-Esquivel; Aamir Dam; Jason Klapman; Douglas G Adler Journal: World J Gastrointest Endosc Date: 2022-01-16